液體活檢在肝細(xì)胞癌診斷及治療中的應(yīng)用
打開文本圖片集
關(guān)鍵詞：肝細(xì)胞癌；液體活組織檢查；腫瘤細(xì)胞，循環(huán)；循環(huán)腫瘤DNA；細(xì)胞外囊泡基金項(xiàng)目：國家“十三五"科技重大專項(xiàng)（2018ZX10302204-001-003）
Abstract：Hepatocelularcarcinomaisoneof the mostcommoncancers，andduetothelackofobviousspecificsymptoms inits earlystage，patientsareoftenintheadvancedstageatthtimeofdiagnosisandtendtohaveapoorprognosis.Timelydiagnosisand ffective treatmentintheearlystagecanhelptoprolongthesurvivaltimeofpatients.Liquidbiopsyisanoninvasivetechniquethat canobtain theinformationof tumorbydetectingandanalyzingrelatedbiomarkers，including circulating tumorcels，circulating tumorDNA，andextracelularvesicles，therebycontributing toearlydiagnosis，molecularpathologicaltyping，andprognosis prediction.Thisarticlereviews theresearchadvancesin theaplicationofliquid biopsyinthediagnosisandtreatmentof hepatocellular carcinoma.
KeyWords：HepatocellularCarcinoma;；LiquidBopsy；eoplasticCels，irculating；CirculatingTumorDA;ExtracellarVesicles Research funding：National Scienceand Technology Major Projects of the 13th Five-Year Plan（2018ZX10302204-001-003）
原發(fā)性肝癌是癌癥死亡的第二大常見原因[1]，其中肝細(xì)胞癌（HCC）是原發(fā)性肝癌的主要類型[2]。（剩余13412字）